First report of proton beam therapy for breast angiosarcoma from the prospective PCG registry

References

• Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1:64–81.
   PubMed Web of Science ®Google Scholar
• Mery CM, George S, Bertagnolli MM, et al. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 2009;115:4055–4063.
   PubMed Web of Science ®Google Scholar
• Brenn T, Fletcher CD. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am J Surg Pathol. 2005;29:983–996.
   PubMed Web of Science ®Google Scholar
• Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37:473–479.
   PubMed Web of Science ®Google Scholar
• Sheth GR, Cranmer LD, Smith BD, et al. Radiation-induced sarcoma of the breast: a systematic review. Oncologist. 2012;17:405–418.
   PubMed Web of Science ®Google Scholar
• Monroe AT, Feigenberg SJ, Mendenhall NP. Angiosarcoma after breast-conserving therapy. Cancer. 2003;97:1832–1840.
   PubMed Web of Science ®Google Scholar
• Jallali N, James S, Searle A, et al. Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg. 2012;203:156–161.
   PubMed Web of Science ®Google Scholar
• Seinen JM, Styring E, Verstappen V, et al. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol. 2012;19:2700–2706.
   PubMed Web of Science ®Google Scholar
• Morgan EA, Kozono DE, Wang Q, et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol. 2012;19:3801–3808.
   PubMed Web of Science ®Google Scholar
• Styring E, Klasson S, Rydholm A, et al. Radiation-associated angiosarcoma after breast cancer: improved survival by excision of all irradiated skin and soft tissue of the thoracic wall? A report of six patients. Acta Oncol. 2015;54:1078–1080.
   PubMed Web of Science ®Google Scholar
• Torres KE, Ravi V, Kin K, et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013;20:1267–1274.
   PubMed Web of Science ®Google Scholar
• Shen CJ, Parzuchowski AS, Kummerlowe MN, et al. Combined modality therapy improves overall survival for angiosarcoma. Acta Oncol. 2017;56:1235–1238.
   PubMed Web of Science ®Google Scholar
• Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26:5269–5274.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz E, Ribelles N, Sanchez-Munoz A, et al. Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. Acta Oncol. 2009;48:1078–1079.
   PubMed Web of Science ®Google Scholar
• Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257–263.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17:260–266.
   PubMed Web of Science ®Google Scholar
• Ghareeb ER, Bhargava R, Vargo JA, et al. Primary and radiation-induced breast angiosarcoma: clinicopathologic predictors of outcomes and the impact of adjuvant radiation therapy. Am J Clin Oncol. 2016;39:463–467.
   PubMed Web of Science ®Google Scholar
• Palta M, Morris CG, Grobmyer SR, et al. Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy. Cancer. 2010;116:1872–1878.
   PubMed Web of Science ®Google Scholar
• Feigenberg SJ, Mendenhall NP, Reith JD, et al. Angiosarcoma after breast-conserving therapy: experience with hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2002;52:620–626.
   PubMed Web of Science ®Google Scholar
• de Jong MA, Oldenborg S, Bing Oei S, et al. Reirradiation and hyperthermia for radiation-associated sarcoma. Cancer. 2012;118:180–187.
   PubMed Web of Science ®Google Scholar
• Depla AL, Scharloo-Karels CH, de Jong MA, et al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur J Cancer. 2014;50:1779–1788.
   PubMed Web of Science ®Google Scholar
• Gunther JR, Rahman AR, Dong W, et al. Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: effectiveness and toxicity after photon or proton treatment. Pract Radiat Oncol. 2017;7:e401–e408.
   PubMed Web of Science ®Google Scholar
• Holliday EB, Kocak-Uzel E, Feng L, et al. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: a case-matched control analysis. Med Dosim. 2016;41:189–194.
   PubMed Web of Science ®Google Scholar
• MacDonald SM. Proton therapy for breast cancer: getting to the heart of the matter. Int J Radiat Oncol Biol Phys. 2016;95:46–48.
   PubMed Web of Science ®Google Scholar
• Patel SA, Lu HM, Nyamwanda JA, et al. Postmastectomy radiation therapy technique and cardiopulmonary sparing: a dosimetric comparative analysis between photons and protons with free breathing versus deep inspiration breath hold. Pract Radiat Oncol. 2017;7;e377–e384.
   PubMed Web of Science ®Google Scholar
• Vogel J, Lin L, Litzky LA, et al. Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma. Int J Radiat Oncol Biol Phys. 2017;99:427–433.
   PubMed Web of Science ®Google Scholar